HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy.

Abstract
Reversible alopecia is a commonly observed, important and distressing complication of chemotherapy. Permanent alopecia, however, is rare after standard-dose therapy, but has occasionally been observed after high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin (CTC). We evaluated the relationships between total exposure to these three compounds and their different metabolites in the high-dose CTC regimen, and the subsequent development of irreversible alopecia. Twenty-four patients received two or three courses of high-dose CTC, each followed by peripheral blood progenitor cell transplantation. Plasma levels of cyclophosphamide, its active metabolite 4-hydroxycyclophosphamide, thiotepa, its active metabolite tepa, and carboplatin were determined, and the area-under-the-plasma concentration-versus-time curves (AUC) of the compounds were calculated. Eight of the 24 patients included in the study developed permanent alopecia, while seven had normal hair regrowth and nine patients developed incomplete and/or thin hair regrowth. The carboplatin AUC and the summed AUC of thiotepa and tepa were both significantly associated with increasing irreversibility of hair loss. These results suggest that high exposure to carboplatin and the sum of the thiotepa and tepa exposure may lead to the development of permanent alopecia. This knowledge could guide therapeutic drug monitoring in order to prevent the occurrence of permanent alopecia and thereby improve the patients' quality of life.
AuthorsM E de Jonge, R A A Mathôt, O Dalesio, A D R Huitema, S Rodenhuis, J H Beijnen
JournalBone marrow transplantation (Bone Marrow Transplant) Vol. 30 Issue 9 Pg. 593-7 (Nov 2002) ISSN: 0268-3369 [Print] England
PMID12407434 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • 4-hydroxycyclophosphamide
  • Cyclophosphamide
  • Thiotepa
  • Carboplatin
  • Triethylenephosphoramide
Topics
  • Adolescent
  • Adult
  • Alopecia (chemically induced, etiology)
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage, adverse effects)
  • Area Under Curve
  • Carboplatin (pharmacokinetics, pharmacology)
  • Cyclophosphamide (analogs & derivatives, blood, metabolism, pharmacokinetics, pharmacology)
  • Drug Evaluation
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoplasms (complications, drug therapy)
  • Thiotepa (metabolism, pharmacokinetics, pharmacology)
  • Triethylenephosphoramide (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: